Loading, Please Wait...
TUCSON, Ariz., July 24, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will report its financial results for the three and six months ended June 30, 2018 after the market close on Tuesday, August 7. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.
|Conference Call & Webcast Details|
|Date:||Tuesday, August 7|
|Time:||4:30pm Eastern Time|
HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.
LifeSci Advisors, LLC
Chief Executive Officer
HTG Molecular Diagnostics